Clinical Trial Scheme of Huangqi Guizhi Wuwu Decoction

Inclusion Criteria: 1\. Patients with colorectal cancer diagnosed by histopathological examination; patients after radical resection of colorectal cancer confirmed by histopathological examination, staged as high-risk II stage (according to CSCO guidelines for diagnosis and treatment of colorectal cancer) or III stage, IV stage (metastatic lesions have been radical resection); 2. Patients who are suitable for receiving oxaliplatin plus capecitabine regimen as adjuvant chemotherapy for 6 months, the cumulative dose of oxaliplatin are expected to exceed 520mg/m2 at least; 3. Aged from 18 to 75 years old, males or females; 4. ECOG score ranges from 0 to 1 5. Seven days before treatment, the functions of major organs (heart, liver, kidney, bone marrow) meet the following criteria: 1. Standard of blood routine examination (without blood transfusion within 14 days) i. Hemoglobin (HB) ≥90g/L； ii. Absolute Neutrophil Count(ANC) ≥1.5×109/L；. iii. Platelet (PLT) ≥80×109/L. 2. Biochemical examination should meet the following standards: * Total bilirubin(TBIL) ≤1.5 times upper normal limit(ULN); * Alanine aminotransferase(ALT) and Aspartate aminotransferase(AST) ≤2.5 times ULN； ③Serum creatinine （Cr）≤1.5 times ULN or Creatinine clearance(CCr) ≥60ml/min; 6.Expected survival time≥12 months; 7. For subjects who have used other chemotherapeutic drugs in the past, they need to go through a clearance period of at least 4 weeks before entering this trial. 8\. The patient who will sign the informed consent form Exclusion Criteria: 1. Patients with original nervous system diseases, including peripheral neuropathy and central neuropathy; 2. Those who are allergic to oxaliplatin or the ingredients of this traditional Chinese medicine; 3. Clinical symptoms of patients with severe damp-heat syndrome of colorectal cancer include: dry mouth, bitter taste in the mouth, sticky sensation in mouth, yellow urine, dry stool, red tongue with yellow ,thick and greasy fur; 4. Patients with neurological disease caused by electrolyte disorders or diabetes; 5. Patients with symptoms of nerve compression caused by various causes; 6. At the same time, patients who receive other neuroprotective therapy, including nerve growth factor, vitamin B and calcium-magnesium mixture; 7. Patients who were treated with oxaliplatin for chemotherapy before; 8. Patients who need radiotherapy within half a year after operation; 9. Pregnant or lactation period women; 10. Patients with cognitive impairment or psychosis; 11. Other patients the investigator considers unsuitable for inclusion.